NEW YORK (360Dx) – San Francisco-based Notable Labs today announced that it has raised $10 million in Series A funding, which it will put toward building its technology platform and team, as well as clinical feasibility studies related to blood cancers.
The firm provides a drug-testing service for oncologists identifying treatment options for blood-cancer patients.
The round was led by Builders VC, a venture capital firm that specializes in early ventures, and it included participation from existing investors, Notable Labs said. The firm noted that since its founding in 2014, it has raised more than $17 million, including the Series A round, from Builder’s VC, Eleven Two Capital, First Round Capital, Founder’s Fund, Fuel Capital, Lightspeed, Upside Partnership, and Y Combinator.
The company has been validating its technology and adding expertise to its team during the past three years, Notable Labs said.
Jim Kim, a founding member and general partner of Builders VC, who has joined Notable’s board of directors, said in a statement that the firm "has developed a unique platform comprised of the latest technologies across biology, IT, and chemistry to address the great need for more efficacious and cost-effective cancer care that is customized for each patient.”
Notable Labs CEO Matthew De Silva said the firm is "working closely with forward-thinking oncologists and researchers at top US and Canadian cancer centers to make personalized combination treatment a reality."